negative-feedback

GNE-1858 是高效的 ATP 竞争性造血祖细胞激酶-1抑制剂，能够抑制野生型(IC50:1.9 nM)、活性模拟突变株 HPK1-TSEE (IC50:1.9 nM)、 HPK1-SA (IC50:4.5 nM)的活性。

Chromenone 1 是一种有效的成骨骨形态发生蛋白(BMP)增强剂，其通过诱导显著的非激酶依赖的负TGFβ反馈，独特地增强了核BMP-Smad信号输出。

SR-29065 是一种选择性 REV-ERBα 激动剂，可在昼夜节律的转录–翻译反馈环中抑制 BMAL1 的转录。SR-29065 可用于评估同时靶向昼夜节律负向调控分支是否可在胶质母细胞瘤模型中产生协同抗肿瘤效应，SR-29065 广泛应用于自身免疫性疾病及昼夜节律研究中。

HRX-0233 是一种小分子 MAP2K4 抑制剂，在 KRAS^G12C 突变型非小细胞肺癌模型中可在无明显毒性的情况下诱导显著的肿瘤回缩，并在 sotorasib 单药治疗过程中阻断受体酪氨酸激酶的反馈激活。HRX-0233 能实现 MAPK 通路的持续抑制，支持其在肺癌、结直肠癌及 AR 阴性前列腺癌研究中的应用。

(+)-UH 232 Maleate 是一种多巴胺受体亚型选择性调节剂，对 D₂受体表现为自身受体优先拮抗剂，对 D₃受体则为部分激动剂。(+)-UH 232 Maleate 选择性结合并阻断中枢多巴胺神经元上的 D₂自身受体，解除其对多巴胺合成与释放的负反馈抑制。(+)-UH 232 Maleate 以较低内在活性 (0.2-0.4) 结合 D₃受体，可部分激活受体信号通路。(+)-UH 232 Maleate 可用于特异性研究多巴胺能神经系统功能。

Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011). Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4 References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011).

(E)-Guggulsterone是一种Guggulsterone的异构体。(E)-Guggulsterone是一种FXR拮抗剂，能够降血脂，还能够诱导血红素氧化酶-1表达、阻断DENV NS2B/3B活性，抑制DENV复制。

Negative control for st-Ht31 . Gorshkov et al (2017) AKAP-mediated feedback control of cAMP gradients in developing hippocampal neurons. Nat.Chem.Biol. 13 425 PMID:28192412 |Vijayaraghavan et al (1997) Protein kinase A-anchoring inhibitor peptides arrest mammalian sperm motility. J.Biol.Chem. 272 4747 PMID:9030527 |Vincent et al (2017) Signaling: Spatial regulation of axonal cAMP. Nat.Chem.Biol. 13 348 PMID:28328917

Cridanimod can increase progesterone receptor (PR) expression, with potential antineoplastic adjuvant activity. Cridanimod is able to induce the expression of PR in endometrial cancer. In combination with a progestin, cancer cells could be eradicated thro

Nafarelin is a gonadotropin-releasing hormone agonist (GnRH agonist) which acts as an analog of GnRH. Nafarelin increases the release of FSH and LH by the anterior pituitary, which in turn leads to an increase of estrogen/progesterone. When administered, Nafarelin has the purpose of causing increase estrogen that will negatively feed back upon hypothalamus to decrease GnRH ( negative feedback loop ) Through negative feedback, Nafarelin causes a decrease in pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Nafarelin may be used in the treatment of estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat central precocious puberty, and to control ovarian stimulation in IVF. It is normally delivered via a nasal spray. Nafarelin acetate is marketed by Searle (now part of Pfizer) under the brand name Synarel.

Preclamol hydrochloride ((-)-3-PPP hydrochloride) 是一种选择性的多巴胺自受体 (Dopamine autoreceptor) 激动剂。它在神经药理学研究中具有独特地位，主要通过激活突触前自受体来产生负反馈，从而抑制多巴胺的合成与释放。与直接阻断突触后受体的传统抗精神病药物不同，Preclamol 能够更微妙地调节多巴胺系统的过度活跃。因此，它被认为在精神分裂症(Schizophrenia)研究中具有重要潜力，特别是用于缓解阳性症状，同时可能减少锥体外系副作用。

Urocortin III (human) 是一种促肾上腺皮质激素释放因子 (CRF) 相关肽。Urocortin III (human) 优先结合并激活CRF-R2，并且具有离散的中枢神经系统和外周分布。Urocortin III (human) 选择性结合 2 型 CRF 受体，mCRF2β、rCRF2α 和 hCRF1 的Ki 值分别为 13.5、21.7 和 >100 nM。Urocortin III (human) 介导Insulin(human) 分泌的生长抑素依赖性负反馈控制。